N-methyl-D-aspartate receptors (NMDARs) play a crucial role in cognition and long-term memory, and have been implicated in a variety of pathological conditions, including stroke, intractable pain, neurodegenerative diseases, and spinal cord injury. We have shown that endogenous neurosteroids, such as pregnenolune sulfate (PS), can specifically modulate NMDA receptor function. Evidence for at least two neurosteroid recognition sites has emerged, one associated with positive modulation and the other with negative modulation. We have demonstrated recently that the direction of modulation by PS is dependent upon which of the NMDA receptor Type-2 subunits is present. NR2A or NR2B confers PS potentiation, whereas NR2C or NR2D confers PS inhibition. To define the structural determinants of receptor subtype-specific neurosteroid modulation, multiple chimeras from NR2B and NR2D parent cDNAs were constructed and analyzed by voltage clamp electrophysiology in Xenopus oocytes containing transiently expressed receptors. We have identified a Steroid Modulatory Domain 1 (SMD1) on NR2B, containing the fourth transmembrane segment (M4) and part of the adjacent M3-M4 linker region. SMD1 is required for rapid potentiation of the NMDA response by PS. In addition to the rapid direct modulation of NMDAK by neurosteroids, there is a slow phase of modulation that is mediated by PKC. The proposed studies build on and extend these findings. ? ? Using site-directedmutagenesis of NR2B/2D and NR2D/2B chimeric subunits to eliminate and then reinstate PS modulation, specific residues that contribute to the response at different NMDAR subtypes will be identified. Cysteine substitution and sulflaydryl-modifying reagents will be used to determine whether these residues are solvent accessible and participate inPS action. Results of these studies will be used to formulate a pharmacological model of NMDAR modulation by neurosteroids. In addition, the possible interactions between the steroid, zinc, and proton modulatory sites will beinvestigated. We will also investigate the mechanism of slow potentiation by PS, which, in contrast to rapid potentiation, requires the action of cellular signal-transduction systems. We will determine whether the domain(s) that control slow potentiation are the same or different from those that control fast potentiation, and will investigate the contributions of rapid and slow potentiation to enhancement of excitotoxicity by PS in neurons and transfected HEK cells. These studies will enhance our understanding of the structural basis that underlies the specificity of neurosteroid modulation at NMDAP, s, and will provide the tools with which to study the biological and pharmacological relevance of endogenous neurosteroids in the nervous system. ? ?

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Research Project (R01)
Project #
5R01MH049469-13
Application #
6824038
Study Section
Molecular, Cellular and Developmental Neurosciences 2 (MDCN)
Program Officer
Winsky, Lois M
Project Start
1992-06-01
Project End
2007-11-30
Budget Start
2004-12-01
Budget End
2005-11-30
Support Year
13
Fiscal Year
2005
Total Cost
$363,375
Indirect Cost
Name
Boston University
Department
Pharmacology
Type
Schools of Medicine
DUNS #
604483045
City
Boston
State
MA
Country
United States
Zip Code
02118
Smith, Conor C; Martin, Stella C; Sugunan, Kavitha et al. (2014) A role for picomolar concentrations of pregnenolone sulfate in synaptic activity-dependent Ca2+ signaling and CREB activation. Mol Pharmacol 86:390-8
Smith, Conor C; Gibbs, Terrell T; Farb, David H (2014) Pregnenolone sulfate as a modulator of synaptic plasticity. Psychopharmacology (Berl) 231:3537-56
Kostakis, Emmanuel; Smith, Conor; Jang, Ming-Kuei et al. (2013) The neuroactive steroid pregnenolone sulfate stimulates trafficking of functional N-methyl D-aspartate receptors to the cell surface via a noncanonical, G protein, and Ca2+-dependent mechanism. Mol Pharmacol 84:261-74
Kostakis, Emmanuel; Jang, Ming-Kuei; Russek, Shelley J et al. (2011) A steroid modulatory domain in NR2A collaborates with NR1 exon-5 to control NMDAR modulation by pregnenolone sulfate and protons. J Neurochem 119:486-96
Eagleson, K L; Gravielle, M C; Schlueter McFadyen-Ketchum, L J et al. (2010) Genetic disruption of the autism spectrum disorder risk gene PLAUR induces GABAA receptor subunit changes. Neuroscience 168:797-810
Berezhnoy, D; Gibbs, T T; Farb, D H (2009) Docking of 1,4-benzodiazepines in the alpha1/gamma2 GABA(A) receptor modulator site. Mol Pharmacol 76:440-50
Berezhnoy, Dmytro; Gravielle, Maria C; Downing, Scott et al. (2008) Pharmacological Properties of DOV 315,090, an ocinaplon metabolite. BMC Pharmacol 8:11
Sadri-Vakili, G; Janis, G C; Pierce, R C et al. (2008) Nanomolar concentrations of pregnenolone sulfate enhance striatal dopamine overflow in vivo. J Pharmacol Exp Ther 327:840-5
Whittaker, Matthew T; Gibbs, Terrell T; Farb, David H (2008) Pregnenolone sulfate induces NMDA receptor dependent release of dopamine from synaptic terminals in the striatum. J Neurochem 107:510-21
Jang, Ming-Kuei; Mierke, Dale F; Russek, Shelley J et al. (2004) A steroid modulatory domain on NR2B controls N-methyl-D-aspartate receptor proton sensitivity. Proc Natl Acad Sci U S A 101:8198-203

Showing the most recent 10 out of 19 publications